Skip to main content Accessibility help
×
  1. Home
  2. Browse subjects
  3. Life Sciences
  4. Biotechnology
  5. Content listing

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1502 results in Biotechnology

Page 40 of 76

  • Preface

  • Edited by Jess G. Thoene, University of Michigan, Ann Arbor
  • Book:
    Small Molecule Therapy for Genetic Disease
    Published online:
    17 November 2010
    Print publication:
    23 August 2010, pp xi-xiv

  • Summary

    The problem of recognition and treatment of rare diseases has been a topic of interest since Representative Henry Waxman held hearings on this issue in 1980. Led by Representative Waxman, clinician/scientists, legislators, patient interest groups, and drug companies all participated in the formation and passage of the Orphan Drug Act of 1983 (PL 97–414). In that legislation, an orphan disease was defined as a condition that affects fewer than 200,000 Americans. In testimony during hearings while the bill was being drafted, it was learned that treatments for more than 100 rare diseases existed but were not being developed because of lack of interest by pharmaceutical companies because of the small market and thus, lack of potential profitability. The Act provided tax incentives for clinical trials of these agents, grants to assist investigators in performing the trials, and a structure at the U.S. Food and Drug Administration (FDA; The Office of Orphan Products; see Chapter 2) to help shepherd applications through the agency. The Act has been an unqualified success. In fact, President Reagan, who initially threatened to veto the legislation, later described it as “…one of the most significant and successful pieces of health care legislation during my presidency…”

    The topics addressed in this book are all rare diseases within the meaning of the Orphan Drug Act. The success of these therapies is recognition of the hard work expended by clinical investigators (many of whom are authors of chapters in this book) to bring successful treatment for these serious and often life-threatening conditions to new drug approval.

Page 40 of 76